Denied in Real Time: Rethinking Patient Advocacy in Medicare Advantage

As we move deeper into analysis of the upcoming proposed rule changes by the Centers for Medicare & Medicaid Services (CMS), many hospitals are still grappling with the unintended consequences of what initially appeared to be strengthened patient protections under CMS-4208-F (MA 2026 Final Rule). While CMS reinforced transparency, standardized notice delivery, and beneficiary appeal rights, the downstream response from Medicare Advantage (MA) plans has shifted utilization management pressures back onto providers, tightening clinical, operational, and financial controls.

A prominent example is the policy implemented by Aetna, which reflects a significant departure from traditional inpatient denial workflows. More broadly, MA plans have introduced several notable operational changes, including the elimination or restructuring of denial-triggered peer-to-peer (P2P) pathways, compressed clinical submission timelines, and a shift toward modified payment methodologies on typical Diagnosis-Related Group (DRG) contracts.  

It remains unclear whether this shift is primarily a response to provider behavior following CMS-4201-F implementation, wherein hospitals increasingly escalated concurrent denials to P2P when the Two-Midnight Rule was perceived to be met. Or it may have been driven by CMS-4208-F’s expectations regarding real-time beneficiary notification through the Integrated Denial Notice (IDN). Most likely, it is a combination of both forces that has prompted MA plans to recalculate their strategies.

The IDN is designed to consolidate multiple denial communications into a single, standardized notice that clearly outlines both coverage and payment determinations, along with associated appeal rights. CMS requires MA plans to issue the IDN whenever an adverse organization determination occurs, including during concurrent review. The intent is to reduce confusion and ensure that beneficiaries receive consistent, actionable information when services are denied, reduced, or terminated.

This requirement has significant implications for hospitals. When an MA plan denies an inpatient level of care while the patient is still hospitalized, that determination must be treated as an adverse decision, with full notice and appeal rights. CMS guidance reinforces that patients must be informed in a timely and meaningful way, even while still receiving care, so they have the opportunity to act on those rights during the hospitalization.

However, this creates a practical challenge. If the patient is already admitted and receiving care, how is the IDN effectively delivered in real time? MA plans are unlikely to hand-deliver notices, and reliance on mailed communication introduces a high likelihood that the patient will be discharged before receiving notification. This gap creates a disconnect between regulatory intent and operational reality.

This is where hospitals may need to consider a more proactive role.

While the responsibility for issuing the IDN remains with the payer, hospitals are often the only party physically present with the patient at the time of the determination. As such, it may be reasonable and operationally necessary for hospitals to notify the patient that their MA plan has issued a denial of an inpatient level of care – and to reinforce their right to appeal.

At that point, an important question emerges: should hospitals also provide the Appointment of Representative (AOR) form (CMS-1696)?

Providing the AOR form at the time of a concurrent denial would allow the patient to designate a representative, such as a family member (or, where appropriate, hospital staff) to assist with the appeals process. While CMS does not require hospitals to distribute the AOR in this context, integrating it into the denial workflow represents a practical strategy to support patient transparency and access to the member appeals process.

Embedding the AOR alongside awareness of the IDN could offer several advantages. It ensures that patients and families are not only informed of the denial, but equipped to act. It creates a pathway to pursue appeals through the member process, which necessitates continued accessibility, given the increasingly constrained provider appeal channels. Most importantly, it aligns with CMS’s broader intent: that beneficiaries are not only notified of their rights, but meaningfully supported in exercising them.

Admittedly, this approach introduces additional operational considerations. Incorporating another form into case management and utilization review workflows requires training, standardization, and clear role delineation. However, as payer pressures intensify through reduced reimbursement, limited concurrent resolution opportunities, and evolving denial methodologies, engaging patients and families as active participants in the appeal process may represent a necessary shift.